Roman Fabbricatore

The project will be focused on increasing awareness and early detection of the disease and generate high-quality data to inform improvement of care.

Experts discussed the clinical implications of the LITESPARK-011 trial of belzutifan plus lenvatinib following a presentation of efficacy findings at ASCO GU.

Three experts in surgery, radiation, and integrative care disclosed the most salient advances and keen insights in their respective fields.

Phase 3 ENVISION trial data revealed a 72.2% probability of remaining event-free among responders to UGN-102 with non-muscle invasive bladder cancer.

Berzosertib plus cisplatin and radiotherapy did not meet the preliminary efficacy end point of complete response rate in this head and neck cancer group.

Clinically relevant variants were detected in 64% of samples, with negative results informing response or ruling out central nervous system lymphomas.

The FDA previously approved the gene therapy as a treatment for high-risk BCG-unresponsive NMIBC with CIS plus or minus papillary tumors in December 2022.

Specialized LLMs, AI-assisted CT scans for early detection, and foundational models democratizing pathology are among emerging technologies in oncology care.

Findings from the phase 3 SWOG 1826/CA209-8UT trial support the regulatory decision for this lymphoma population.

The resubmission occurred after discussions with the FDA in January 2026, where the agency requested additional data to support its review.

The phase 3 TALAPRO-3 study met its primary end point, showing a clinically meaningful reduction in the risk of progression or death in HRR-mutant HSPC.

Benjamin Garmezy, MD, discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

For patients with more aggressive disease, the addition of chemotherapy to the ARPI/ADT backbone may optimize efficacy outcomes without comprising safety.

Twenty patients with low- to intermediate-risk localized prostate cancer underwent successful implantation with the antiandrogen-eluting implants.

By harnessing investigator-generated data, companion diagnostics, and biomarker-directed treatment selection, clinicians can optimize care for HSPC.

Bridget Koontz, MD, discussed evaluating the role of concurrent hormone therapy and brachytherapy for prostate cancer that she presented at ASCO GU.

An independent data monitoring committee advised that the risks associated with emergent secondary hematologic malignancies may outweigh the benefits.

No grade 3 or greater treatment-related AEs or discontinuations were observed among patients with bladder cancer treated with the investigational agent.

Key abstracts across genitourinary cancers were presented across multiple oral sessions examining investigational treatments in select patient groups.

Oncologists discussed key abstracts assessing AI models for treatment selection, AKT inhibition, and PARP inhibition in specific prostate cancer types.

SBRT was considered safe among patients with advanced renal cell carcinoma when added to the immunotherapy combination.

Patrick Borgen, MD, discussed using ctDNA for “molecular interception” to de-escalate surgery and minimize AEs in biology-driven breast cancer care.

Jason Molitoris, MD, PhD, discussed 2025 data on proton therapy for oropharyngeal cancer, highlighting immune preservation and reduced long-term AEs.

New biomarker data showed a correlation between magnitude and durability of serum erythropoietin suppression by casdatifan for this group.

Those with intellectual disabilities were less likely to undergo expedient prostate biopsy following an elevated PSA result.

Mauro Cives, MD, discussed "immune niches," neoantigen mapping, and strategies to minimize adverse effects in healthy tissue for this treatment modality.

Findings from the phase 1b/2 OrigAMI-4 trial support the regulatory decision for this regimen in this advanced head and neck cancer population.

Cytokines such as IL-17B, TNF-α, and IL-6 are essential in driving neuroendocrine differentiation and “reprogramming” healthy tissue.

A Prescription Drug User Fee Act date of December 18, 2026, has been set for tirabrutinib in this relapsed/refractory group.

Although many clinical trials end due to strategic reasons, easing inclusion criteria and reducing potential operational failure may mitigate terminations.